Tag Archives: Merrimack Pharmaceuticals

June, 2018

July, 2016

  • 6 July

    Merrimack’s NSCLC Drug Receives Fast Track Designation from the FDA

    CAMBRIDGE, Mass., July 6, 2016 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted seribantumab, also known as MM-121, Fast Track designation for development in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has …

June, 2016

October, 2015

May, 2015